Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3721-3728

  Köhne, Claus Henning ^a   Wils, J ^b   Lorenz, M ^b   Schoffski P ^b   Voigtmann, R ^b   Bokemeyer, C ^b   Lutz, M ^b   Kleeberg, U ^b   Ridwelski, K ^b   Souchon, R ^b   El Serafi, M ^b   Weiss, U ^b   Burkhard, O ^b   Ruckle H ^b   Lichinitser, M ^b   Langenbuch, T ^b   Scheithauer, W ^b   Baron, B ^b   Couvreur, M L ^b   Schmoll, H J ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; STOMATITIS; ADULT; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17744418861     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.122     Document Type: Article

References (19)

1. Köhne CH, Kretzschmar A, Wils J: First-line chemotherapy for colorectal carcinoma: We are making progress. Onkologie 21;280-289, 1998
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. Rustum YM, Trave F, Zakrzewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 4:165-170, 1987
4. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
5. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs-Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
6. de Gramont A, Bosset JF, Milan C, et al: A randomized trial comparing monthly low-dose leucovorin / fluorouracil bolus with bimonthly high-dose leucovorin/fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
7. Ardalan B, Singh G, Silberman H: A randomized phase I and II study of short-term infusion of high- dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6:1053-1058, 1988
8. Haas NB, Hines JB, Hudes GR, et al: Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11:181-185, 1993
9. Ardalan B, Chua L, Tian EM, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
10. Könne CH, Wilke H, Hecker H, et al: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol 6:461-466, 1995
11. Könne CH, Schöffski P, Wilke H, et al: Effective biomodulation by leucovorin of high dose infusional fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 16:418-426, 1998
12. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
13. Leichman CG, Fleming TR, Muggia FM et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
14. O'Dwyer PJ, Manola J, Valone FH et al: Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-L-aspartic acid. J Clin Oncol 19:2413-2421, 2001
15. Blijham G, Wagener T, Wils J et al: Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 14:2266-2273, 1996
16. Tomiak A, Vincent M, Kocha W, et al: Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: Prohibitive toxicity? Am J Clin Oncol 23:94-98, 2000
17. Van Cutsem E, Douillard JY, Kohne CH: Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 345:1351-1352, 2001
18. Vanhoefer U, Harstrick A, Köhne CH et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907-913, 1999
19. Morton RF, Goldberg RM, Sargent DJ, et al: Oxaliplatin (OXAL) or CPT-11 combined with FU/Leucovorin (LV) in advanced colorectal cancer (CRC): An NCCTG/CALGB study. Proc Am Soc Clin Oncol 20:125a, 2001 (abstr 495)